Скачать с ютуб Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients в хорошем качестве

Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients

Caspian Oliai, MD, MS, University of California, Los Angeles, Los Angeles, CA, discusses Orca-T, a high-precision immune therapy that uses stem cells and immune cells derived from allogeneic donors to leverage highly purified, polyclonal donor regulatory T-cells to control alloreactive immune responses. The Orca-T manufacturing process retains cells with therapeutic benefits while removing those that pose potential risks. Dr Oliai highlights data from a sub-group analysis of older patients with hematological malignancies enrolled in a multicenter Phase Ib single-arm trial (NCT04013685). These patients were diagnosed with either acute myeloid leukemia (AML), lymphoid or mixed phenotype leukemia, myelodysplastic syndromes (MDS), or chronic myeloid leukemia (CML) in the chronic phase. The participants received a myeloablative regimen of intravenous busulfan, fludarabine, and thiotepa (BFT), followed by Orca-T. Disease outcomes with this treatment approach were very promising, and no transplant-related deaths occurred. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.